Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials
Pooled result · Mortality, septic shock (subgroup)Result — go to the resultRelative risk 0.92 95% CI 0.86–0.97Authors' conclusion
Administration of non-adrenergic vasopressors was significantly associated with reduced mortality in patients with septic shock.
Study context
- Population
- Adults receiving vasopressor therapy for vasodilatory shock or perioperative vasoplegia (septic shock, cardiac surgery, non-cardiac surgery)
- Participants
- 5,715 adults · 51 randomized controlled trials (RCTs)
- Comparison
- Non-adrenergic vasopressors vs adrenergic vasopressors alone or placebo
- Outcome
- Mortality at longest follow-up
Methodological detailsrandom-effects meta-analysis, 17 studies low risk of bias (Cochrane RoB 2)
- Random-effects meta-analysis
- 17 studies low risk of bias (Cochrane RoB 2)
Pooled result
Mortality, septic shock (subgroup)
Relative risk
0.92
95% CI 0.86–0.97
P = 0.03
Events by group
Non-adrenergic vs Adrenergic alone or placebo
RR 0.92 (95% CI 0.86–0.97); P = 0.03
As reported in the abstract
Further pooled results
| Outcome | Non-adrenergic | RR (95% CI) | P value | |
|---|---|---|---|---|
| Mortality, cardiac surgery (subgroup) · longest follow-upI2 = 12% | 8.3% | 0.82 (0.55–1.22) | P = 0.32 | |
| Mortality, non-cardiac surgery (subgroup) · longest follow-upI2 = 0% | 2.3% | 0.66 (0.31–1.41) | P = 0.28 | |
| 0.20.5125Relative risk (log scale) |
- Mortality, cardiac surgery (subgroup) — No significant mortality difference; comparator 47/412
- 11%
- Mortality, non-cardiac surgery (subgroup) — No significant mortality difference; comparator 18/383
- 4.7%
Original publication
Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials. Crit Care. Published 30 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →